Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aptevo Therapeutics Inc (APVO)

Aptevo Therapeutics Inc (APVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,994
  • Shares Outstanding, K 3,233
  • Annual Sales, $ 32,420 K
  • Annual Income, $ -40,450 K
  • 60-Month Beta 2.70
  • Price/Sales 0.81
  • Price/Cash Flow N/A
  • Price/Book 1.79

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -2.27
  • Number of Estimates 2
  • High Estimate -2.24
  • Low Estimate -2.30
  • Prior Year -4.20
  • Growth Rate Est. (year over year) +45.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.93 +20.49%
on 07/14/20
9.78 -14.62%
on 07/07/20
-0.83 (-9.04%)
since 07/02/20
3-Month
4.62 +80.78%
on 05/18/20
11.73 -28.81%
on 06/25/20
+3.32 (+66.00%)
since 05/04/20
52-Week
2.94 +183.61%
on 03/13/20
14.14 -40.95%
on 08/08/19
-4.68 (-35.90%)
since 08/02/19

Most Recent Stories

More News
Aptevo Therapeutics Engages Piper Sandler to Sell its RUXIENCE(R) and IXINITY(R) Royalty Streams & Milestones

SEATTLE, WA / ACCESSWIRE / July 21, 2020 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific...

PFE : 38.39 (+0.10%)
APVO : 8.35 (+3.21%)
Thinking about buying stock in Ekso Bionics, Apple Inc, GNC Holdings, Microsoft Corp, or Aptevo Therapeutics?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EKSO, AAPL, GNC, MSFT, and APVO.

AAPL : 438.66 (+0.67%)
APVO : 8.35 (+3.21%)
EKSO : 6.34 (-2.31%)
GNC : 0.5500 (unch)
MSFT : 213.29 (-1.50%)
Aptevo Therapeutics to receive Seven Year Quarterly Royalty Payment Stream from Pfizer for Sales of Rituximab Biosimilar

Published Articles Suggest the Global Market for Rituximab Biosimilars Could Potentially be over $1 Billion Per YearRoyalty Stream Relates to Agreement Acquired in Aptevo Spin-off from Emergent BioSolutions...

APVO : 8.35 (+3.21%)
Aptevo Therapeutics and Alligator Bioscience Present new Preclinical Data for ALG.APV-527 at the PEGS Virtual Interactive Global Summit

and LUND, , /PRNewswire/ -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology...

APVO : 8.35 (+3.21%)
Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the PEGS Virtual Interactive Global Summit

New Preclinical Data Show That ALG.APV-527 has Potential for a Favorable Safety Profile

APVO : 8.35 (+3.21%)
Medexus Provides an Update on the IXINITY(R) Acquisition and its Overall Business in the COVID-19 Environment

Medexus Pharmaceuticals Inc. (the "Company" or "Medexus") (TSX-V: MDP, OTCQB: PDDPF) today provided an update on its business in light of the recent transformative acquisition of the commercial hematology...

APVO : 8.35 (+3.21%)
Aptevo Therapeutics Reports First Quarter 2020 Financial Results

Aptevo Therapeutics Inc. (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, today provided...

APVO : 8.35 (+3.21%)
Aptevo Therapeutics Regains Compliance With Nasdaq Listing Requirements

SEATTLE, WA / ACCESSWIRE / April 14, 2020 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™...

APVO : 8.35 (+3.21%)
What Makes Aptevo Therapeutics Inc. (APVO) a New Buy Stock

Aptevo Therapeutics Inc. (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

APVO : 8.35 (+3.21%)
Aptevo Therapeutics Reports 2019 Financial Results and Provides Business Update

APVO : 8.35 (+3.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Trade APVO with:

Business Summary

Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics...

See More

Key Turning Points

2nd Resistance Point 8.64
1st Resistance Point 8.50
Last Price 8.35
1st Support Level 8.11
2nd Support Level 7.86

See More

52-Week High 14.14
Fibonacci 61.8% 9.86
Fibonacci 50% 8.54
Last Price 8.35
Fibonacci 38.2% 7.22
52-Week Low 2.94

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar